[Form 4] UiPath, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 highlights: On 06/30/2025 Genworth Holdings, Inc., which remains the controlling stockholder of Enact Holdings, Inc. (ticker ACT), sold 691,152 Enact common shares to the issuer under an April 30, 2025 Share Repurchase Agreement. The transaction was coded “S” (sale) and priced at $35.4867 per share, a volume-weighted figure set by the agreement. Following the sale, Genworth still owns 120,243,555 shares, representing approximately 81 % of the outstanding stock, and reports the position as direct ownership.

The filing signals incremental execution of the parent-level liquidity strategy while modestly reducing Enact’s public float through an issuer buyback. No derivative securities were involved, and no change in board or executive relationships was disclosed.

Positive

• Issuer-level share repurchase removes 691,152 shares from the public float without open-market pressure.
• Rule 10b5-1 structured sale reduces insider-trading risk perception and adds transparency to Genworth’s divestiture plan.

Negative

• Continued parent-level selling indicates Genworth may keep monetizing its stake, potentially leading to future share overhang.
• Control concentration unchanged; minority shareholders still have limited influence with Genworth retaining ~81 % ownership.

Insights

Equity Analyst

TL;DR: Parent sold 0.6 % of stake back to Enact; float shrinks slightly, control unchanged, neutral-to-mildly positive for remaining shareholders.

The 691 k-share block represents roughly 0.4 % of Enact’s 173 m share base (implied from 81 % ownership figure), so the financial impact on EPS and book value is immaterial. However, buying directly from Genworth avoids open-market pressure and signals ongoing commitment to capital return after the April 2025 repurchase agreement. Genworth’s continued 81 % ownership means governance dynamics and dual-class risk are unchanged. From a liquidity standpoint, the parent’s gradual selldown may foreshadow future secondary offerings, but the small size and fixed pricing limit market read-through today.

Corporate Governance Specialist

TL;DR: Minor insider sale via structured agreement; control remains concentrated, governance profile unchanged.

The transaction was executed pursuant to a Rule 10b5-1-compliant repurchase contract, reducing concerns of opportunistic trading. Yet, it reinforces Genworth’s ability to monetize its stake outside public markets, limiting minority shareholders’ influence. Because the ownership percentage did not move materially, board composition and related-party considerations stay the same. I view the event as low impact but a useful data point on the parent’s divestiture timeline.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yang June

(Last) (First) (Middle)

C/O UIPATH, INC.

ONE VANDERBILT AVENUE, 60TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UiPath, Inc. [ PATH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/26/2025		A(1)		16,064(2)	A	$0.00	59,171	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This grant was made pursuant to the issuer's non-employee director compensation policy.

2. Includes 16,064 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement. Each Annual Director RSU vests on the earlier of the date of the following year's annual meeting (or the date immediately prior to the next annual meeting, if the non-employee director's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or the first anniversary of the date of grant, in each case subject to the director's continued service through such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	Brad Brubaker, as attorney in fact	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Enact (ACT) shares did Genworth sell on 06/30/2025?

691,152 common shares were sold to the issuer.

What price did the shares trade at under the repurchase agreement?

The weighted average price was $35.4867 per share, calculated per the agreement terms.

How many Enact shares does Genworth hold after the transaction?

Genworth now owns 120,243,555 shares, about 81 % of Enact’s outstanding stock.

Was the transaction open-market or a private agreement?

It was executed under a Share Repurchase Agreement dated 04/30/2025, not in the open market.

Did the filing involve any derivative securities?

No, Table II shows zero derivative activity in this Form 4.

Does this sale change Enact’s governance structure?

No, Genworth remains the controlling shareholder, so governance dynamics are unchanged.